EHA 2025 | The shift toward fixed-duration combinations in the treatment of CLL

We have got lots of new treatments for patients with CLL and of course as the trials develop, we’re moving away where possible from, particularly in the frontline, from continuous BTK inhibitors to where possible thinking about fixed-duration therapies. And at the moment that’s a combination of BCL2 inhibitors plus either a monoclonal antibody or BTK inhibitors. So the field is definitely moving towards fixed-duration therapies for the frontline setting. And because of that, it means then that now we’re increasingly looking and interested when we hear about all the trial updates as to what’s happening with retreatment. So when we reuse venetoclax once it’s already been used before, it’s encouraging to see that patients still respond to it and they can get durable responses. This is the first time since we’ve been able to use venetoclax and ibrutinib and in the future we’ll probably be able to use acalabrutinib and venetoclax where we might see gain experience with retreatment from BTK inhibitors as well. So it’ll be interesting to see how the retreatment data develops going forward. We’ve also got other drugs that have encouraging data and now we’re starting to see trials using combinations of these drugs. So, for example, the non-covalent BTK inhibitors such as pirtobrutinib and also BTK degraders. It’ll be interesting to see what combinations in what trials come up in the near future for these new drugs.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.